386 related articles for article (PubMed ID: 15997692)
1. [Favourable result for temozolomide in recurrent high-grade glioma].
Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
4. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan DT; Poon WS; Chan YL; Ng HK
Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
[TBL] [Abstract][Full Text] [Related]
7. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
8. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
[TBL] [Abstract][Full Text] [Related]
12. Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Trippoli S; Pelagotti F; Messori A; Vacca F; Vaiani M; Maltoni S
Drugs R D; 2003; 4(5):285-91. PubMed ID: 12952497
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
14. BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2004 May; 11(4):374-5. PubMed ID: 15080950
[TBL] [Abstract][Full Text] [Related]
15. A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.
Patil VM; Abhinav R; Tonse R; Epari S; Gupta T; Jalali R
Indian J Cancer; 2016; 53(4):558-561. PubMed ID: 28485350
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
[TBL] [Abstract][Full Text] [Related]
17. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Yung WK; Prados MD; Yaya-Tur R; Rosenfeld SS; Brada M; Friedman HS; Albright R; Olson J; Chang SM; O'Neill AM; Friedman AH; Bruner J; Yue N; Dugan M; Zaknoen S; Levin VA
J Clin Oncol; 1999 Sep; 17(9):2762-71. PubMed ID: 10561351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
